The reactivity of [Pt₂(μ-S)₂(PPh₃)₄] towards difunctional chloroacetamide alkylating agents: Formation of cyclized or bridged products [PDF]
, 2011 The reactions of [Pt₂(μ-S)₂(PPh₃)₄] towards some bis(chloroacetamide) alkylating agents have been investigated. Reaction with one mole equivalent of the hydrazine-derived compound ClCH₂C(O)NHNHC(O)CH₂Cl led to the cyclized product [Pt₂{SCH₂C(O)NHNHC(O ...
Fitchett, Christopher M. +3 more
core +2 more sources
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]
, 2014 BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol +5 more
core +2 more sources
Monocytosis and Multiple Myeloma: treatment-related acute leukaemia?
Surgical and Experimental Pathology, 2022 Background Therapy-related acute monocytic leukemias in patients with plasma cell dyscrasias are infrequent. Case presentation We here present a case of a 60 year old female who developed an acute monocytic leukemia two years after the diagnosis of ...
Cristina Veronica Trinidad Esparza +4 more
doaj +1 more source
Electrochemistry of potentially bioreductive alkylating quinones : Part 1. Electrochemical properties of relatively simple quinones, as model compounds of mitomycin- and aziridinylquinone-type antitumour agents [PDF]
, 1990 The influence of methyl-, hydroxy and amino substituents on the electrochemical behaviour of simple 1,4-naphtho-and 1,4-benzoquinones, model compounds of many quinoid antitumour agents, in aqueous media was studied. Significant changes in electrochemical
Bos, M. +9 more
core +2 more sources
EO9 (Apaziquone): from the clinic to the laboratory and back again [PDF]
, 2013 EO9 (Apaziquone) is a bioreductive drug that has a chequered history. It underwent clinical trial but failed to show activity in phase II clinical trials when administered i.v.
Aamdal +75 more
core +1 more source
Restoration of Sensitivity in Chemo [PDF]
, 2013 Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Despite multimodal treatments including surgery, chemotherapy and radiotherapy the prognosis remains poor and relapse occurs regularly.
Boxhammer, Veronika +10 more
core +1 more source
DNA Damage Induced by Alkylating Agents and Repair Pathways
Journal of Nucleic Acids, 2010 The cytotoxic effects of alkylating agents are strongly attenuated by cellular DNA repair processes, necessitating a clear understanding of the repair mechanisms. Simple methylating agents form adducts at N- and O-atoms.
Natsuko Kondo +3 more
doaj +1 more source
DNA Damaging Agents in Chemical Biology and Cancer
CHIMIA, 2020 Despite their toxicity, DNA alkylating drugs remain a cornerstone of anticancer therapy. The classical thinking was that rapidly dividing tumour cells left more of its DNA in an exposed single-stranded state, making these rapidly dividing cells more ...
Basilius Sauter, Dennis Gillingham
doaj +1 more source
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma [PDF]
, 2018 Background: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM).
Chen, Yi +12 more
core +2 more sources
Microsomal superoxide anion production and NADPH-oxidation in a series of 22 aziridinylbenzoquinones [PDF]
, 1989 Several 2,5-bis(1-aziridinyl)-1,4-benzoquinones (BABQs) can be activated to alkylating species by reduction of the quinone moiety. On the other hand, cytotoxicity of these compounds can be induced by redox cycling.
Koster, Andries Sj. +3 more
core +3 more sources